
U.S. drug developer Amneal Pharmaceuticals AMRX.O rises 4.09% to $8.15 in premarket trading
J.P.Morgan upgrades to "overweight" from "neutral"; lifts PT from $9 to $12, ~42% upside to last close of $7.83
Says co well-positioned for sustainable high single-digit growth, driven by strong portfolio of complex generics and biosimilars
Expects AMRX to outperform peers significantly on successful launch of Crexont, used to treat Parkinson's disease, and AvKARE's (co's independent subsidiary) impressive growth
Stock rated "buy" on avg; median PT is $11 - LSEG
AMRX down 1.13% so far this year, as of Friday's close